Nemonoxacin

Drug Profile

Nemonoxacin

Alternative Names: Nemonoxacin malate sodium chloride; Taigexyn; TG-873870

Latest Information Update: 23 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Procter & Gamble
  • Developer TaiGen Biotechnology
  • Class Antibacterials; Piperidines; Quinolones; Small molecules
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Community-acquired pneumonia
  • Phase II Diabetic foot ulcer
  • Phase Unknown Skin and soft tissue infections

Most Recent Events

  • 30 May 2017 Preregistration for Community-acquired pneumonia in China (IV)
  • 27 Mar 2017 Launched for Community-acquired pneumonia in China (PO) before March 2017
  • 25 Aug 2016 Nemonoxacin sub-licensed to Productos Cientficos for development and commercialisation in Latin America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top